Business
Spectral and Estor expand distribution relationship
Spectral and Estor expand distribution relationship.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\nTORONTO, Oct. 16 /CNW/ - Spectral Diagnostics Inc. (\"Spectral\"), (TSX:\nSDI), today announced the signing of an exclusive, five year distribution\nagreement with Estor S.p.A. (\"Estor\") for commercial sales of its novel sepsis\ntest, the Endotoxin Activity Assay (\"EAA(TM)\"), in Italy. This agreement\nbuilds upon the initial arrangement signed with Estor in June of this year.\nEstor, a leading supplier of medical devices for the treatment of sepsis\ntechnologies in Italy, will market and distribute Spectral's new assay\ninstrument and its reagents for use in emergency departments and intensive\ncare units.\n\n\"We are very pleased to solidify a long term relationship with Estor,\"\nstated Dr. Paul Walker, President & CEO of Spectral. \"Early acceptance of our\nEAA(TM) product in Italy has been positive and this new exclusive arrangement\nshould provide for consistent growth in the Italian marketplace over the term\nof the agreement,\" added Dr. Walker.\n\n\"As the distributor of PMX, a device for the extracorporeal removal of\nendotoxins in septic patients, we definitely need a proven diagnostic tool to\nbundle with the therapy. Estor began its marketing campaign with the\nsuccessful launch of EAA(TM) during the last Italian meeting of the ICU\nscientific society (SIAARTI) held in Perugia on October 11th and 12th\", stated\nDr. Gualtiero Guadagni, Sales & Marketing Director of Estor.\n\nSpectral is a developer of innovative technologies for rapid diagnostics.\nSpectral provides accurate and timely information to clinicians enabling the\nearly initiation of appropriate and targeted therapy. Current products include\nrapid diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range\nof other biological reagents. Spectral's common shares are listed on The\nToronto Stock Exchange: SDI.\n\nInformation in this news release that is not current or historically\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. Implicit in this information, the future outlook\nof Spectral and anticipated events or results are assumptions based on beliefs\nof Spectral's senior management as well as information currently available to\nit. While these assumptions were considered reasonable by Spectral at the time\nof preparation, they may prove to be incorrect. Readers ar...